- Report
- February 2024
- 181 Pages
Europe
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 150 Pages
Global
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 90 Pages
South Korea
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 70 Pages
India
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 90 Pages
United States
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 90 Pages
France
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4170EUR$4,750USD£3,578GBP
- Report
- February 2024
- 70 Pages
Russia
From €4170EUR$4,750USD£3,578GBP
- Report
- August 2023
- 150 Pages
North America
From €4170EUR$4,750USD£3,578GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4170EUR$4,750USD£3,578GBP
- Report
- August 2023
- 70 Pages
Spain
From €4170EUR$4,750USD£3,578GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4170EUR$4,750USD£3,578GBP
- Report
- October 2022
- 70 Pages
Africa
From €4170EUR$4,750USD£3,578GBP
- Report
- March 2019
- 90 Pages
Europe
From €4170EUR$4,750USD£3,578GBP

Toujeo is a long-acting insulin used to treat adults with type 1 and type 2 diabetes. It is a part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. Toujeo is a once-daily, long-acting insulin that helps to control blood sugar levels. It is designed to provide a steady, consistent level of insulin throughout the day, helping to reduce the risk of hypoglycemia.
The Endocrine and Metabolic Disorders Drugs market is a rapidly growing sector, with a wide range of products available to treat a variety of conditions. Companies in this market include Sanofi, Novo Nordisk, Eli Lilly, Merck, and AstraZeneca. Show Less Read more